Elvira Faw, NP
Nurse Practitioner · Albany, NYNPI 1417422056
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 742 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 742 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$3K
- Johnson & Johnson$3K
- UCB, Inc.$1K
- Lilly USA, LLC$1K
- Pfizer$900
- plus $4K from 28 others
What the payments were for
- Food & beverage$15,03297%
- Education$5113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 115 | $2,870 |
| AbbVie | 129 | $2,742 |
| Johnson & Johnson | 156 | $2,616 |
| UCB, Inc. | 68 | $1,291 |
| Lilly USA, LLC | 41 | $1,102 |
| Pfizer | 54 | $900 |
| GSK | 30 | $818 |
| E.r. Squibb & Sons, L.L.C. | 20 | $444 |
| Novartis | 22 | $412 |
| Mallinckrodt Hospital Products Inc. | 18 | $378 |
| AstraZeneca(2 entities) | 17 | $354 |
| Boehringer Ingelheim | 10 | $347 |
| Fresenius Kabi USA, LLC | 8 | $160 |
| Genentech USA, Inc. | 8 | $154 |
| Sobi, Inc | 7 | $136 |
| Sandoz | 5 | $116 |
| Fidia Pharma USA Inc. | 6 | $86 |
| ANI Pharmaceuticals, Inc. | 3 | $84 |
| Radius Health, Inc. | 3 | $76 |
| Actelion Pharmaceuticals US, Inc. | 3 | $52 |
| Sanofi | 2 | $51 |
| Organon | 2 | $51 |
| Aurinia Pharma U.S., Inc. | 2 | $50 |
| Antares Pharma, Inc. | 2 | $41 |
| Ultragenyx Pharmaceutical Inc. | 2 | $30 |
| Vertex | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Urovant Sciences Inc | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| IBSA Pharma Inc. | 1 | $17 |
| Abbott | 1 | $16 |
| Heron Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,543 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 94 | $846,448 |
| EnbrelEtanercept | 55 | $339,099 |
| Humira(Cf) PenAdalimumab | 32 | $337,863 |
| Orencia ClickjectAbatacept | 38 | $211,687 |
| Humira PenAdalimumab | 18 | $198,662 |
| OtezlaApremilast | 50 | $194,889 |
| TremfyaGuselkumab | 11 | $145,042 |
| Xeljanz XrTofacitinib Citrate | 19 | $103,851 |
| KevzaraSarilumab | 22 | $96,994 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $96,202 |
| Hydroxychloroquine Sulfate | 264 | $9,585 |
| MethotrexateMethotrexate Sodium | 362 | $7,944 |
| Leflunomide | 117 | $5,017 |
| Celecoxib | 145 | $3,896 |
| Prednisone | 359 | $2,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Otezla | $2,870 | $533,989105 claims |
| Johnson & JohnsonTremfya | $2,616 | $145,04211 claims |
| SanofiKevzara | $51 | $96,99422 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,291 | $96,20211 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $23 | $1,95228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Albany
- Valerie StanleyAlbany$55K
- Marie SchongarAlbany$25K
- Elizabeth NardacciAlbany$18K
- Stephen JonesAlbany$18K
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.